Search clinical trials for: Mozobil

Total 105 results

Stanford University
Orca Biosystems, Inc.

Recruiting

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Myelodysplastic Syndromes | Myeloproliferative Disorders | Acute Leukemia | Chronic Myelogenous Leukemia | Allogeneic Hematopoietic Cell Transplantation (HCT) | Advanced Hematologic Malignancies

United States
Lawrence D Recht
Sanofi

Recruiting

Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma

Glioblastoma | Malignant Glioma | Gliosarcoma | Glioblastoma With Primitive Neuronal Component | Oligodendroglial Component Present

United States
IRCCS San Raffaele
Fondazione Telethon

Recruiting

Combination of Ibuprofen, G-CSF and Plerixafor as Stem Cells Mobilization Regimen in Patients Affected by X-CGD (XCGD-MOBI)

Chronic Granulomatous Disease X-linked (X-CGD)

Italy
Emory University
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Neurovascular Transduction During Exercise in Chronic Kidney Disease (NeurovEx)

Renal Insufficiency, Chronic

United States
National Institute of Allergy and Infectious Diseases...

Recruiting

A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

Infections | Warts | Neutropenia | Leukopenia | Myelokathexis

United States
Hospital Infantil Universitario Niño Jesús, Madrid...
Universitat Autonoma de Barcelona; Instituto de Investigación Sanitaria de... and other collaborators

Completed

Lentiviral-mediated Gene Therapy of Fanconi Anemia Patients Subtype A (FANCOLEN-1)

Fanconi Anemia

Spain
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI); Genzyme, a Sanofi Company; American Association...

Completed

Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma

United States
Ensoma

Completed

Study Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MGTA-145 in Healthy Volunteers as a Single Agent or in Combination With Plerixafor

Healthy Volunteers

United States
Ensoma
National Marrow Donor Program

Terminated

MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies

Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Healthy Donors | Related Donors Donating PBSC to a Family Member

United States
Jonsson Comprehensive Cancer Center
California Institute for Regenerative Medicine (CIRM)

Terminated

Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer (NYESO SCT)

Sarcoma | Unresectable Malignant Neoplasm | Locally Advanced Malignant Neoplasm | HLA-A*0201 Positive Cells Present | NY-ESO-1 Positive

United States
National Heart, Lung, and Blood Institute (NHLBI)
St. Jude Children's Research Hospital

Completed

Peripheral Blood Stem Cell Collection for Sickle Cell Disease (SCD) Patients

Sickle Cell Disease

United States
Center for International Blood and Marrow Transplant...
Sanofi; Genzyme, a Sanofi Company

Completed

A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor

Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Hodgkin's Disease | Related Donors Donating Peripheral Blood Stem Cells (PBSC) to a Family Member

United States
University of Alberta
Alberta Innovates Health Solutions

Active, not recruiting

Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)

Diabetes Mellitus, Type 1

Canada
Fred Hutchinson Cancer Center
National Heart, Lung, and Blood Institute (NHLBI); Rocket Pharma Limited

Active, not recruiting

Gene Therapy for Fanconi Anemia

Fanconi Anemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Scleroderma Treatment With Autologous Transplant (STAT) Study (STAT)

Systemic Scleroderma

United States
4Living Biotech

Withdrawn

Plerixafor in Acute Respiratory Distress Syndrome Related to COVID-19 (Phase IIb) (LEONARDO)

COVID-19 | COVID-19 Acute Respiratory Distress Syndrome

France, Bulgaria
St. Jude Children's Research Hospital
Doris Duke Charitable Foundation

Withdrawn

Peripheral Blood Stem Cell Collection From Patients With Sickle Cell Disease (SCD) Using Plerixafor

Sickle Cell Disease

United States
National Institute of Allergy and Infectious Diseases...

Completed

Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome

Infections | Warts | Neutropenia | Myelokathexis | Hypogammaglobulinemia

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center

Terminated

CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

T-cell Non-Hodgkin Lymphoma

United States
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Withdrawn

A Dose Finding Study of CycloSam® Combined With External Beam Radiotherapy

Osteosarcoma | Bone Metastases

United States
Surbhi Sidana, MD

Completed

MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma

Multiple Myeloma

United States
Fred Hutchinson Cancer Center

Terminated

O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas

Glioblastoma | Gliosarcoma

United States
National Institute of Allergy and Infectious Diseases...

Terminated

Collection of Peripheral Blood Stem Cells Using G-CSF and Plerixafor in Normal Volunteers

Normal Physiology

United States
Bradley Connor

Enrolling by invitation

Efficacy of AEMCOLO (Rifamycin SV MMX) in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO)

Gastrointestinal Disease | Small Intestinal Bacterial Overgrowth | Gastrointestinal Infection

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers

Healthy

United States
Siddhartha Ganguly

Completed

Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)

Multiple Myeloma

United States
Sanofi
Genzyme, a Sanofi Company

Completed

An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells

Multiple Myeloma

Sweden, Estonia, Belgium, Lithuania
Cosmo Technologies Ltd

Completed

Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D

Diarrhea-predominant Irritable Bowel Syndrome

Belgium, Germany, Italy, Spain
Washington University School of Medicine

Terminated

Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Acute Lymphocytic Leukemia

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

An Evaluation of Safety and Efficacy of Escalating Doses of AMD3100 to Mobilize CD34+ Cells in Healthy Volunteers

Healthy Volunteers

United States
Jonsson Comprehensive Cancer Center
Novartis Pharmaceuticals

Withdrawn

TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma (NYSCT MM)

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | HLA-A*0201 Positive Cells Present | NY-ESO-1 Positive Tumor Cells Present

United States
E. Steve Woodle
Sanofi-Synthelabo

Unknown

Quantitating the Impact of Plerixafor

Transplants and Implants

United States
Washington University School of Medicine
Karyopharm Therapeutics Inc

Completed

Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
Instituto Nacional de Ciencias Medicas y Nutricion...

Unknown

Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission

Acute Myeloid Leukemia | Acute Lymphoid Leukemia

Mexico
Weill Medical College of Cornell University
Millennium Pharmaceuticals, Inc.

Completed

Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma

Multiple Myeloma

United States
Gian Paolo Fadini
University Hospital Padova

Terminated

Plerixafor in Diabetic Wound Healing (MOZOBL07740)

Diabetes | Critical Limb Ischemia | Wounds

Italy
CCTU- Cancer Theme
Sanofi; National Institute for Health Research, United Kingdom; Stand Up To Cancer and other collaborators

Completed

To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers (CAM-PLEX)

Colorectal Cancer Metastatic | Ovarian Serous Adenocarcinoma | Pancreatic Adenocarcinoma Metastatic

United Kingdom
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Withdrawn

HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection

Stage III Adult Hodgkin Lymphoma | Stage IV Adult Hodgkin Lymphoma | Human Immunodeficiency Virus 1 Positive | Stage I Adult Hodgkin Lymphoma | Stage II Adult Hodgkin Lymphoma | Stage I Adult Non-Hodgkin Lymphoma | Stage II Adult Non-Hodgkin Lymphoma | Stage III Adult Non-Hodgkin Lymphoma | Stage IV...

United States
Lawrence Recht
National Cancer Institute (NCI)

Completed

Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma

Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Adult Ependymoblastoma | Adult Medulloblastoma | Adult Pineoblastoma | Adult Supratentorial Primitive Neuroectodermal Tumor (PNET) | Adult Oligodendroglial Tumors

United States
Weill Medical College of Cornell University
Genzyme, a Sanofi Company

Completed

Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States
National Cancer Institute (NCI)

Completed

Collection of Transplant Stem Cells for Plasma Cell Myeloma

Multiple Myeloma | Plasma Cell Myeloma

United States
University of Colorado, Denver
Sanofi

Completed

Autologous CD117+ Progenitor Cell Mobilization for Lung Transplantation

Pulmonary Fibrosis | Cystic Fibrosis | COPD

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

AMD 3100 (Mozobil Plerixafor) to Mobilize Stem Cells for Donation

Healthy

United States
David Rizzieri, MD
Genzyme, a Sanofi Company; Celgene Corporation

Completed

Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)

Leukemia, Lymphocytic, Chronic, B-Cell

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells

Non-Hodgkin Lymphoma

United States
Patrick Y. Wen, MD
Massachusetts General Hospital; Dana-Farber Cancer Institute; Brigham and Women... and other collaborators

Terminated

Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma

High Grade Glioma: Glioblastoma (GBM) | High Grade Glioma: Gliosarcoma | Anaplastic Astrocytoma (AA) | Anaplastic Oligodendroglioma (AO) | Mixed Anaplastic Oligoastrocytoma (AOA)

United States
Hospital Universitario Dr. Jose E. Gonzalez

Unknown

Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood Transplantation

Lymphoma, Non-Hodgkin | Myeloma | Lymphoma, Hodgkin | Stem Cell Transplant Complications

Mexico
Stephen Couban
Genzyme, a Sanofi Company

Completed

Healthy Donor Study II - Comparing Plerixafor With G-CSF and Plerixafor

Malignant Lymphoma, Stem Cell Type

Canada

Search clinical trials for: Mozobil

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations